UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 902

Sortiert nach

Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician

European journal of nuclear medicine and molecular imaging, 2017-08, Vol.44 (Suppl 1), p.41-54

2017

Volltextzugriff (PDF)

Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers

European journal of cancer (1990), 2017-10, Vol.84, p.114-120

2017

Volltextzugriff (PDF)

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis

Gynecologic oncology, 2022-03, Vol.164 (3), p.498-504

2022

Volltextzugriff (PDF)

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial

Annals of oncology, 2023-12, Vol.34 (12), p.1152-1164

2023

Volltextzugriff (PDF)

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients

Gynecologic oncology, 2019-05, Vol.153 (2), p.304-311

2019

Volltextzugriff (PDF)

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia

Gynecologic oncology, 2015-07, Vol.138 (1), p.55-61

2015

Volltextzugriff (PDF)

Clinical behavior of low grade serous ovarian carcinoma: An analysis of 714 patients from the Ovarian Cancer Association Consortium (OCAC)

Gynecologic oncology, 2017-06, Vol.145, p.14-14

2017

Volltextzugriff (PDF)

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC)

Gynecologic oncology, 2017-02, Vol.144 (2), p.250-255

2017

Volltextzugriff (PDF)

GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer

Annals of oncology, 2018-11, Vol.29, p.ix86-ix86

2018

Volltextzugriff (PDF)

Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis

Annals of oncology, 2018-10, Vol.29, p.viii29-viii29

2018

Volltextzugriff (PDF)

A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium

British journal of cancer, 2015-12, Vol.113 (11), p.1534-1540

2015

Volltextzugriff (PDF)

Germline BRCA1 / 2 testing practices in ovarian cancer: Current state and opportunities for new directions

Gynecologic oncology, 2016-01, Vol.140 (1), p.90-94

2016

Volltextzugriff (PDF)

How to assess the potential interest of aspirin in ovarian cancer?

Cancer epidemiology, 2015-10, Vol.39 (5), p.790-791

2015

Volltextzugriff (PDF)

849: PI3K/mTOR dual inhibition modulates Bcl-2 family proteins expression and sensitizes ovarian carcinoma cells to ABT-737

European journal of cancer (1990), 2014-07, Vol.50, p.S207-S207

2014

Volltextzugriff (PDF)

Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment

Seminars in cancer biology, 2022-11, Vol.86 (Pt 3), p.207-223

2022

Volltextzugriff (PDF)

Survival with Cemiplimab in Recurrent Cervical Cancer

The New England journal of medicine, 2022-02, Vol.386 (6), p.544-555

2022

Volltextzugriff (PDF)

8046 POSTER Clinical Characteristics of Patients With Sporadic or BRCA Mutated Ovarian Cancer

European journal of cancer (1990), 2011, Vol.47, p.S541-S541

2011

Volltextzugriff (PDF)

7143 POSTER Prognosis of Patients With Metastatic Renal Cell Carcinoma (mRCC) With Primary Resistance to Sunitinib: Is There Any Active Treatment?

European journal of cancer (1990), 2011, Vol.47, p.S518-S518

2011

Volltextzugriff (PDF)

Novel Molecular Targets in Endometrial Cancer: Mechanisms and Perspectives for Therapy

Biologics, 2024-01, Vol.18, p.79-93

2024

Volltextzugriff (PDF)

Supported self-management as an innovative model of care for advanced gynecologic cancer patients with malignant bowel obstruction: A qualitative study

Gynecologic oncology, 2020-10, Vol.159, p.314-315

2020

Volltextzugriff (PDF)

788P Circulating human papillomavirus DNA as a biomarker of response in advanced cervical cancer

Annals of oncology, 2021-09, Vol.32, p.S757-S758

2021

Volltextzugriff (PDF)

1664MO Tumor-naïve methylomes and fragmentomes during pembrolizumab (P) in metastatic cancer patients

Annals of oncology, 2022-09, Vol.33, p.S1303-S1304

2022

Volltextzugriff (PDF)

50P Can we learn from failures? A systematic review and metanalysis of phase III trials in platinum resistant ovarian cancer

ESMO open, 2023-02, Vol.8 (1), p.100830, Article 100830

2023

Volltextzugriff (PDF)

806P Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers

Annals of oncology, 2023-10, Vol.34, p.S537-S537

2023

Volltextzugriff (PDF)

Clinical behavior of low grade serous ovarian carcinoma: Ananalysis of 714 patients from the Ovarian Cancer Association Consortium (OCAC)

Gynecologic oncology, 2017-06, Vol.145, p.14

2017

Volltextzugriff (PDF)

1 – 25 von 902

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(763)
Mit Volltextzugriff
(748)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician

Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia

Clinical behavior of low grade serous ovarian carcinoma: An analysis of 714 patients from the Ovarian Cancer Association Consortium (OCAC)

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC)

GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer

Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis

A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium

Germline BRCA1 / 2 testing practices in ovarian cancer: Current state and opportunities for new directions

How to assess the potential interest of aspirin in ovarian cancer?

849: PI3K/mTOR dual inhibition modulates Bcl-2 family proteins expression and sensitizes ovarian carcinoma cells to ABT-737

Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment

Survival with Cemiplimab in Recurrent Cervical Cancer

8046 POSTER Clinical Characteristics of Patients With Sporadic or BRCA Mutated Ovarian Cancer

7143 POSTER Prognosis of Patients With Metastatic Renal Cell Carcinoma (mRCC) With Primary Resistance to Sunitinib: Is There Any Active Treatment?

Novel Molecular Targets in Endometrial Cancer: Mechanisms and Perspectives for Therapy

Supported self-management as an innovative model of care for advanced gynecologic cancer patients with malignant bowel obstruction: A qualitative study

788P Circulating human papillomavirus DNA as a biomarker of response in advanced cervical cancer

1664MO Tumor-naïve methylomes and fragmentomes during pembrolizumab (P) in metastatic cancer patients

50P Can we learn from failures? A systematic review and metanalysis of phase III trials in platinum resistant ovarian cancer

806P Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers

Clinical behavior of low grade serous ovarian carcinoma: Ananalysis of 714 patients from the Ovarian Cancer Association Consortium (OCAC)

Suchergebnisse filtern